TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Impact of leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of wet episodes per 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe intraventricular hemorrhage
Endpoint domain: Mortality/survival
Primary endpoint: Standing systolic BP fell below 85 mm Hg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Standing diastolic BP <45 mm Hg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean maximal decreases in standing systolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Suppressive imbalance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotional status (MADRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Complete IVI scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Task performance time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HRV parameters (low frequency, high frequency, standard deviation of RR intervals, root mean square of differences)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in STAI, Tension-POMS, and Vigour-POMS scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Requirement of rescue analgesics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delivery or fetal death before 35 weeks
Endpoint domain: Mortality/survival
Primary endpoint: Serious adverse fetal or neonatal events
Endpoint domain: Adverse events/effects
Primary endpoint: Visual nearpoint changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart rate variability changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean plasma ascorbate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postintervention Lp(a) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with anemia corrected or achieving hemoglobin increments of >20g/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adherence to best-practice guidelines for VTE risk assessment and prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early non-response to antipsychotic medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean pain difference scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angiographic restenosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Plaque burden assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reduction in symptoms of OWS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion rates of the study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: quality of life (QoL) deterioration
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: moment of recurrence
Endpoint domain: Mortality/survival
Primary endpoint: mean IDS-SR scores at moment of recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal allograft survival
Endpoint domain: Mortality/survival
Primary endpoint: Biopsy-proven acute cellular rejection
Endpoint domain: Adverse events/effects
Primary endpoint: Blood pressure response to Ang II
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total triathlon time improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of anal fissure
Endpoint domain: Adverse events/effects
Primary endpoint: Antibacterial efficacy for Propionibacteria and Micrococcaceae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: New-onset diabetes after kidney transplantation (NODAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Risk of C trachomatis conjunctivitis
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with DAS28 <= 3.2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: successful clinical outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: ventilation changes due to hyperoxia and hypoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Annual cost of intensive therapy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Visual verification in observation tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful puncture rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of artery stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Freedom from MACE at 30 days
Endpoint domain: Adverse events/effects
Primary endpoint: patient retention
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: days in treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: positive urine test rates for opiates
Endpoint domain: Adverse events/effects
Primary endpoint: Unprotected anal sex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Doctors' willingness to have patients with schizophrenia on their practice list
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Referral rates to specialists for patients with schizophrenia
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Perceptions of violence associated with patients with schizophrenia
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: NASA-TLX scores for mental demand, effort, and frustration
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Amount of biofilm removed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in size of the wheal or erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Movement of the hemiplegic upper extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of coronary calcium score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite of all ASCVD events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fasting plasma glucose (FPG) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fundus findings stability or improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walking Limitations
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: duration of infusion set survival
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: minor oozing in the first 24 hours
Endpoint domain: Adverse events/effects
Primary endpoint: bleeding after removal of the pack
Endpoint domain: Adverse events/effects
Primary endpoint: hospital stay
Endpoint domain: Resource use
Primary endpoint: Mean MED
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SPHERE score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: postural stability indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proximal femur BMD reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lumbar spine BMD reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rewarming endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tidal volume delivered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impairment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: early return of bowel function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of noncompliance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Serum TT3, TT4, FT3, FT4 and S-TSH contents
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: PSA screening interest
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: General nasal symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS score for nasal stuffiness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rhinorrhea symptoms improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in cognitive control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mF-G score greater than six
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEF(25%-75%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Crash related injury risk
Endpoint domain: Mortality/survival
Primary endpoint: overt gastrointestinal bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: medio-lateral sway range during quiet standing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: extra healthy life gained
Endpoint domain: Mortality/survival
Primary endpoint: disability-free life gained
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: aggressive behaviour
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Scar area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical cure rate at test-of-cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: early thrombotic events
Endpoint domain: Mortality/survival
Primary endpoint: Retention
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Interview responses
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Appropriateness of prophylaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left atrial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total emptying fractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cholesterol content reduction in lipoproteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: mean endothelial cell loss 3 months after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ipsilateral shoulder or arm symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reporting of arm swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of maximal gall-bladder emptying
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: postprandial residual gall-bladder volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: basal sphincter of Oddi pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Chronic tinnitus distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: β-Apo-13-carotenone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: motor function of lower limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: activity of daily living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 1-min Apgar score <7
Endpoint domain: Adverse events/effects
Primary endpoint: Necessity of intensive care unit
Endpoint domain: Adverse events/effects
Primary endpoint: Health anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in muscle power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: five-repetition sit-to-stand test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in [(11)C]raclopride binding in the limbic striatum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased dopamine levels in the limbic striatum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proinflammatory index of periimplantitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: computer usage
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: serum cathepsin D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of invasive coronary angiograms without a class I indication for revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Knowledge regarding sexual healthcare
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Attitude regarding sexual healthcare
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-efficacy concerning sexual healthcare
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Peripheral insulin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Gene expression of PPARGC1A and OXPHOS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: KI viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vertebral body height improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kyphotic wedge angle improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjacent segment fractures
Endpoint domain: Adverse events/effects
Primary endpoint: Gastric half emptying time (t 1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to negative fluid balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical outcome scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Median 24-h gastric pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Integrated 24-h gastrin output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Overall examination scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pass rate of OSCE assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic intracranial haemorrhage rate
Endpoint domain: Adverse events/effects
Primary endpoint: Prevention of hypertrophic scars and keloids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement of scar effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: decreased risk of death at 90 days
Endpoint domain: Mortality/survival
Primary endpoint: increased survival time
Endpoint domain: Mortality/survival
Primary endpoint: increased renal replacement-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Completion of 6-month HAV/HBV vaccine series
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Willingness to communicate about organ donation intentions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency of apneas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of apnea associated with severe bradycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adherence to treatment with medicines
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: DOCE (Device-Oriented Composite Endpoint)
Endpoint domain: Mortality/survival
Primary endpoint: Craving for smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forced inspiration manoeuvers volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rescue doses of analgesics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: SRB scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: incidence of severe OM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma activity of DAO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GIMD score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expressions of HSP70 mRNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: long-term remission sustaining rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety (no complications)
Endpoint domain: Adverse events/effects
Primary endpoint: SGRQ symptom score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Hypermethylation of the CDH1 promoter region
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduced E-cadherin expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Operative time to teach the Pomeroy technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Distant progression (DP) after androgen deprivation therapy (ADT)
Endpoint domain: Mortality/survival
Primary endpoint: Quality of life (QLQ-C30 and QLQ PR-25 scores)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvements in attention
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Local recurrence free (LRF) as first event
Endpoint domain: Mortality/survival
Primary endpoint: Prevention of fainting responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean inflammation grading score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean aggressiveness grading score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet concentration of 5-HT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma ACTH level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen Extraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Emotional impact of visual impairment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: General alcohol craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum lactate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: peak-season rhinitis scores on the visual-analogue scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak-season daily nasal symptom diary scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: midseason overall quality-of-life scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in dietary behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal 6-Minute Walking Distance (6MWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 90-day readmission rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Detection of lupus anticoagulant (LA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thrombin generation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-Xa levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean morning IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Percentage of patients achieving target IOP <18 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: average pad weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average number of pads
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: On-treatment gastrointestinal adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Mean changes from baseline in FVC at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Composite of death, MI and stroke rate
Endpoint domain: Mortality/survival
Primary endpoint: Three year cumulative costs
Endpoint domain: Resource use
Primary endpoint: incidence of confirmed infection within 14 days
Endpoint domain: Adverse events/effects
Primary endpoint: number of unplanned hospital admissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: number of unplanned surgical curettage
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention